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with limb/girdle disease (median DFS 82.4 months; 95 % 
CI 0.0–184.7) and pts with other primary sites (median 
DFS 18.3 months; 95 % CI 8.0–28.5) (p = 0.052). Grade 
≥3 toxicities occurred in 20 pts (20.8 %), leading to dose 
reductions, delays, and treatment discontinuation in five 
cases. There was no treatment-related death.
Conclusion Our data confirm benefit of ACT with regard 
to DFS and OS in pts with high-risk STS, greatest for limb/
girdle STS.
Keywords Adjuvant · Sarcoma · High risk · 
Chemotherapy · Epirubicin · Ifosfamide
Introduction
Soft tissue sarcomas (STS) are a heterogeneous group 
of malignancies which derive from mesenchymal tissue 
(Clark et al. 2005). STS are rare tumors, which globally 
make up about 1 % of all malignancies with an overall 
incidence of 3–5 cases/100.000 inhabitants/year (Siegel 
and Naishadham 2013). The group includes more than 70 
histological subtypes (Mastrangelo et al. 2012) with differ-
ent natural history, age at the diagnosis, and site of onset. 
STS arising in the limbs and girdles are by far the most 
frequent, accounting up to 75 % of the total (Fletcher et al. 
2013).
The prognosis may vary among different histotypes, 
with the most important prognostic factors being tumor 
size, grade, and depth (Coindre et al. 1996). Some tools, 
such as the detection of sarcoma circulating tumor cells, 
are currently under investigation, and they may provide a 
way to monitor risk of relapse and metastatic spread, which 
might play a role in the future in clinical decision-making, 
if validated in large clinical studies (Satelli et al. 2014).
Abstract 
Purpose The role of adjuvant chemotherapy (ACT) 
for soft tissue sarcomas (STS) is not standard practice. 
We investigated effectiveness and tolerability of ACT 
in patients (pts) with operated high-risk STS in clinical 
practice.
Methods Medical records of pts with localized STS 
referred to Istituto Oncologico Veneto, Padova, from Janu-
ary 1, 2003 to July 07, 2012 were reviewed. Data were col-
lected for pts with high-risk STS (size ≥5 cm, high grade 
and stage III). For those who received ACT, regimens used, 
drug doses, number of cycles, toxicity, and reasons for dose 
reduction or treatment interruption were recorded. Disease-
free survival (DFS) and overall survival (OS) were calcu-
lated with the Kaplan–Meier method.
Results Out of 96 eligible pts, median age 62 years, 36 
received ACT after loco-regional treatment. Median DFS 
was 29.6 months (95 % CI 13.2–46.0) in pts receiving 
ACT and 7.8 months (95 % CI 3.9–11.7) in untreated pts 
(p < 0.0001); median OS was 67.0 months (95 % CI 25.4–
108.6) in treated and 33.7 months (95 % CI 23.3–44.2) 
in untreated pts (p = 0.005). Among pts receiving ACT, 
a significant difference in DFS was observed between pts 
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The treatment of soft tissue sarcomas relies on a multi-
modality approach, with surgery representing the corner-
stone (ESMO/European Sarcoma Network Working Group 
2012), combined with ancillary therapies such as radiother-
apy or hyperthermic isolated limb perfusion, which allow 
to obtain an optimal local control of the disease minimizing 
the need for demolitive procedures (Rosenberg et al. 1982; 
Rossi et al. 2003).
Nonetheless, a great proportion of patients with high-
risk sarcoma eventually develop metastatic disease (Zagars 
et al. 2003).
This has prompted the conduction of trials with the 
aim of testing the role of adjuvant chemotherapy in pre-
venting relapse and eventually improving survival. A first 
generation of trials in the late 1970s tested the efficacy of 
anthracyclines, alone or in various combination regimens, 
with discordant findings. The Sarcoma Meta-Analysis Col-
laboration (SMAC) (1997), which included patients’ indi-
vidual data from such trials, showed a significant advan-
tage in terms of disease-free survival (DFS) in patients 
who received adjuvant chemotherapy but no difference 
with regard to overall survival (OS). Yet, in the subgroup 
of patients with STS of the extremities, a significant benefit 
in OS was observed for patients receiving chemotherapy. A 
second generation of randomized trials was run in the early 
1990s, characterized by more rigorous selection criteria, 
by the introduction of ifosfamide and the intensification 
of doses with the support of hematopoietic growth factors. 
This generation of studies yielded discordant results, with a 
study of the Italian Sarcoma Group demonstrating a benefit 
both in DFS (p = 0.04) and OS (p = 0.03) (Frustaci et al. 
2001) for patients receiving adjuvant chemotherapy and, on 
the other hand, a European Organization for Research and 
Treatment of Cancer (EORTC; Woll et al. 2012) trial show-
ing no difference in OS (p = 0.72) and DFS (p = 0.51) 
between patients treated with adjuvant chemotherapy and 
controls. A new meta-analysis confirmed a marginal effi-
cacy of adjuvant chemotherapy, with a significant decrease 
in local recurrence rate (OR 0.73, p = 0.02), distant recur-
rence rate (OR 0.67, p = 0.001), and overall recurrence 
rate (OR 0.67, p = 0.0001) in patients receiving chemo-
therapy with doxorubicin-based regimens or with doxoru-
bicin/ifosfamide combination, which translated into a gain 
in OS (OR 0.77, p = 0.01) and absolute risk reduction of 
death of 6 %, when only doxorubicin plus ifosfamide-based 
regimens were considered (Pervaiz et al. 2008). The more 
recently pooled analysis of the two EORTC phase III trials 
(Le Cesne et al. 2014) conducted on individual patient data 
of 819 patients with median follow-up of 8.2 years shows 
that tumor size, high histological grade, and R1 resection 
are independent adverse prognostic factors for relapse-free 
survival (RFS) and OS, whereas adjuvant chemotherapy is 
an independent favorable prognostic factor for RFS but not 
for OS. Moreover, gender and age correlate with RFS, with 
males and patients >40 years having a significantly better 
RFS in the treatment arms, and on the contrary female gen-
der and age <40 years being associated with a marginally 
worse OS. Patients with R1 resection had a significantly 
better RFS and OS favoring adjuvant CT arms.
We planned our study in order to evaluate the efficacy 
and safety of adjuvant chemotherapy in patients with high-
risk sarcomas in patients treated at our Institution in com-
mon clinical practice, outside clinical trials.
Methods
Medical records of patients with non-metastatic STS refer-
ring to the Units of Medical Oncology 1 and 2 of the Isti-
tuto Oncologico Veneto of Padua from January 1, 2003 to 
July 31, 2012 were reviewed.
All patients aged ≥18 years with high-risk STS, defined 
as tumor size >5 cm, deep location, high grade, and stage 
III of the classification of the American Joint Committee on 
Cancer (AJCC) 2010 (Edge et al. 2010), were considered 
eligible. STS with specific histologic types such as pedi-
atric-type sarcomas (i.e., rhabdomyosarcoma, Ewing sar-
coma), GISTs, and carcinosarcomas were not considered 
for this study.
Data collected included histological subtype, perfor-
mance status (PS; Oken et al. 1982), other local therapies 
(radiotherapy, hyperthermic isolated limb perfusion), and 
type of surgery. With regard to patients receiving adjuvant 
chemotherapy, chemotherapy regimen, drug doses, and 
number of cycles, along with toxicity and reasons for dose 
reduction or treatment interruption were recorded. Tox-
icities were evaluated according the Common Terminol-
ogy Criteria for Adverse Events version 3.0 (CTCAE v3.0; 
Trotti et al. 2003).
DFS, defined as the time between surgery and disease 
local or metastatic recurrence, and OS, defined as the time 
between surgery and death for any cause, were evaluated. 
For patients lost at follow-up, survival was obtained by 
consulting the demographic services of patient’s city of res-
idence, with disease status being censored for DFS. For this 
type of study, formal consent was not required.
Statistical analysis was performed using SPSS software 
(SPSS for Windows, version 15.0. Chicago, SPSS Inc.) For 
the estimates of survival, we used Kaplan–Meier product-
limit method, comparisons between groups were performed 
using the log-rank test, and hazard ratio (HR) was calcu-
lated using the Cox regression; the association between cat-
egorical and ordinal variables was assessed by means of the 
X2 test and the Mann–Whitney U test, respectively.
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Results
Out of 331 patients with STS, 96 patients were eligible. 
Of these, 36 received adjuvant chemotherapy (ACT). Sixty 
patients did not receive adjuvant treatment (NACT).
Patients’ characteristics
The most frequent histological subtypes both in the 
ACT and in the NACT group were leiomyosarcoma 
(22.2/21.7 %), liposarcoma (22.2/26.7 %), undifferenti-
ated pleomorphic sarcoma (19.4/16.7 %), synovial sarcoma 
(11.1/8.3 %), and malignant peripheral nerve sheath tumors 
(8.3/6.7 %). Patients’ characteristics are reported in Table 1.
In the ACT group median age was 49 years (range 
19–75 years), baseline PS was 0 or 1, respectively, in 34 
and two patients. Twenty-seven patients (75 %) had associ-
ated diseases, mostly low grade according to CIRS (Linn 
et al. 1968), three grade 3 and no grade 4 (Table 1). No 
patient had abnormal echocardiogram of the 27 examined. 
Out of three patients with a history of ischemic cardiomyo-
pathy, two were treated with pegylated liposomal doxoru-
bicin and one with conventional therapy (Table 2).
In the NACT group, median age was 66 years (range 
22–88 years), pts overall displayed a higher degree of 
frailty, with PS being 0 in 33, 1 in 16 and 2 in two patients. 
Forty-six patients (76.6 %) presented some comorbid-
ity (Table 1). Thirty-nine patients (65 %) had cardiovas-
cular risk factors, with some degree of impairment at the 
echocardiogram in three subjects (5 %).
Efficacy
After a median follow-up of 28.2 months (range 3.4–
114.3), disease recurrence was observed in 19 patients in 
the ACT group, and in 45 patients in the NACT group. 
The median DFS was 29.6 months in the ACT (95 % CI 
13.2–46.0) and 7.8 months in the NACT group (95 % CI 
3.9–11.7), HR 0.32 (95 % CI 0.183–0.565); (p < 0.0001; 
Fig. 1).
Overall 51 patients died, 13 in the ACT group and 38 
in the NACT group, of which 37 were attributable to sar-
coma—11 in the ACT group and 26 in the NACT group. 
Table 1  Patients’ characteristics
ACT (%) NACT (%)
Age
 <65 years 30 (83.3) 26 (43.3)
 ≥65 years 6 (16.7) 34 (56.7)
Gender
 Male 16 (44.4) 33 (55)
 Female 20 (55.6) 27 (45)
PS
 0 34 (94.4) 33 (55)
 1–2 2 (5.6) 18 (30)
 Not available 0 (0) 9 (15)
Histologic subtypes
 Leiomyosarcoma 8 (22.2) 13 (21.7)
 Others 28 (77.8) 47 (78.3)
Tumor site
 Limbs/girdles 18 (50) 37 (61.7)
 Others 18 (50) 23 (38.3)
Comorbidities (grade)
 G 1–2 25 (69.4) 41 (68.3)
 G 3 2 (5.6) 5 (8.3)
 G 4 0 (0) 0 (0)
Not available 9 (25) 14 (23.3)
Comorbidities (typology)
 Hypertension 13 (36.1) 29 (48.3)
 Diabetes 3 (8.3) 6 (10)
 Arrhythmias 1 (2.8) 6 (10)
 Obesity 7 (19.4) 7 (11.7)
 History of ischemic heart disease 3 (8.3) 4 (6.7)
 Dyslipidemia 9 (25) 4 (6.7)
 Smoke (with ex-smokers) 9 (25) 10 (16.7)
Center for surgery
 IOV/other referral centers 8 (22.2) 17 (28.3)
 Peripheral centers 7 (19.4) 14 (23.3)
 Not available 21 (58.4) 29 (48.4)
T
 1 4 (11.1) 0 (0)
 2 31 (86.1) 60 (100)
 Not available 1 (2.8) 0 (0)
Grade
 2 2 (5.6) 1 (1.7)
 3 34 (94.4) 59 (98.3)
Stage
 II 2 (5.6) 0 (0)
 III 34 (94.4) 60 (100)
Infiltrated margins
 Yes 9 (25) 23 (38.3)
 No 20 (55.6) 26 (43.3)
 Not available 7 (19.4) 11 (18.4)
Radiotherapy
 Yes 21 (58.3) 31 (51.7)
Table 1  continued
ACT (%) NACT (%)
 No 15 (41.7) 29 (48.3)
 Not available 18 (50) 27 (45)
Metastasis
 Yes 14 (38.9) 38 (63.3)
 No 22 (61.1) 22 (36.7)
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The median OS was 67.0 months in the ACT group (95 % 
CI 25.4–108.6) and 33.7 in the NACT group (95 % CI 
23.3–44.2), HR 0.41 (95 % CI 0.219–0.779); (p = 0.005; 
Fig. 2).
When considering for the survival analysis of only 
patients who died of disease, a significant difference was 
observed between the two groups, with median OS of 
29.6 months in the ACT group and 18.0 months in the 
NACT group; p = 0.008.
Globally, median DFS for patients with limb/girdle STS 
was 82.4 months (95 % CI 0.0–184.7) versus 18.3 months 
(95 % CI 8.0–28.5) for patients with STS of other sites, 
p = 0.052 (Fig. 3).
A significant difference was observed for OS, but not 
for DFS, in patients with PS 0 compared to patients with 
PS 1–2, both in the ACT group (median OS 110.3 vs. 
21.9 months; p = 0.012) and in the NACT group (median 
OS 44.0 vs. 17.7 months; p < 0.001).
No difference was found according to other factors (i.e., 
age, tumor size, deliver of radiotherapy, gender).
For patients in the ACT group, mean number of (neo)
adjuvant chemotherapy courses delivered was five. Thirty 
patients (83.3 %) received more than three courses, and six 
patients (16.7 %) received three or less courses. Disease 
recurrence did occur in 17 patients receiving more than 
three courses, and in two patients receiving three or less 
courses. With regard to the number of chemotherapy cycles 
administered, no difference in survival was observed.
Dose intensity (DI), defined as the amount of drug deliv-
ered per time unit (mg/m2 for week), was calculated for 
patients in the ACT group. Nine patients (29 %) needed a 
dose reduction and five patients (16 %) a dose delay, with 
26 patients (72.2 %) receiving a mean DI ≥ 85 %.
Table 2  Adjuvant chemotherapy regimens
Schedule (each 3 weeks) No. of patients
Pegylated liposomal doxorubicin: 50 mg/mq day 1 q28 1
Pegylated liposomal doxorubicin: 30 mg/mq day 1
Ifosfamide: 3 g/mq days 1, 2, 3
1
Doxorubicin 37.5 mg/mq days 1, 2
Ifosfamide: 3 g/mq days 1, 2, 3
2
Epirubicin: 60 mg/mq days 1, 2
Ifosfamide: 3 g/mq days 1, 2, 3 or 1.8 g/mq days 1–5
32
Fig. 1  DFS according to adjuvant chemotherapy (ACT vs. NACT)
Fig. 2  OS according to adjuvant chemotherapy (ACT vs. NACT)
Fig. 3  DFS in the ACT group according to the primary tumor site
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Toxicity
Severe (grade 3–4 according to CTCAE v3.0) non-hema-
tological and hematological toxicities occurred in 20 
patients (55.6 %), leading to dose reductions, dose delays, 
and treatment discontinuation in five cases (13.9 %). 
There was no treatment-related death. Thirty-one patients 
(86.1 %) experienced hematological toxicity, with ane-
mia being present in 80.5 %, neutropenia in 58.3 %, and 
thrombocytopenia in 36.1 % of patients (Table 3). Ten 
patients (27.7 %) experienced febrile neutropenia, suc-
cessfully managed with no further complications. Non-
hematological toxicity occurred in 30 patients (83.3 %), 
the most common being nausea/vomiting (58.3 %), fatigue 
(19.4 %), mucositis (11.1 %), other gastrointestinal tox-
icities (diarrhea, constipation etc.) (13.9 %), and other less 
frequent toxicities (52.8 %) (i.e., thromboembolic events, 
infections) (Table 4).
Discussion
Adjuvant treatment of localized STS is still a debated 
issue (ESMO 2012; Comandone 2014). With all the limits 
and cautions of a retrospective study, our study provides 
real-life data on the efficacy and tolerability of adjuvant 
chemotherapy.
Given the rarity of the disease, a cohort of 96 patients 
can be considered a reliable sample that is likely 
representative of the patient normally seen in routine clini-
cal practice. In our study, in order to minimize possible 
disease-related biases for group comparison, we considered 
for inclusion only those patients with radically resected sar-
coma at high risk of relapse. Indeed, eventual benefits of 
adjuvant chemotherapy seem likely to be limited to high-
grade STS, as a recent analysis of more than 3200 patients 
included in the French Sarcoma Group database shows 
(Italiano et al. 2014). Such an advantage has been found in 
another recently published mono-institutional retrospective 
study (Schenone et al. 2014).
Nevertheless, as expected, the NACT group included on 
average older patients, with more than a half being 65 years 
or older, compared to less than a fifth in the ACT group, 
and less performing patients, with 30 % of patients in the 
NACT having ECOG PS 1–2 versus 5.6 % in the ACT 
group. Comorbidity did not differ in the two groups.
Our study demonstrated a benefit provided by adju-
vant chemotherapy, with regard to both DFS and OS. One 
may argue that OS in patients not undergoing adjuvant 
chemotherapy may be shorter due to concomitant disease 
and older age, yet the benefit in OS for patients in the 
ACT group holds true even if we exclude patients who 
died because of unknown causes. Survival analysis com-
paring patients with an age cutoff of 65 years in both 
groups did not show any significant statistical difference 
neither for DFS nor for OS, whereas patients with PS 0 
had a better survival both in the treated group and in not 
treated group.
Moreover, even if OS may indeed be influenced by a 
higher prevalence of frail patients in the NACT group, 
this condition does not factor in for DFS, which mainly 
depends on the characteristics of the disease that are homo-
geneous in both groups. Also, even if the majority of the 
patients have stage III disease both in the NACT and ACT 
group, patients having tumor stages II and III are not iden-
tical between the two groups, and this should at least in part 
be taken into account for the great variability in DFS (29.6 
vs. 7.8 months).
Median survival, both recurrence-free survival 
and overall survival, in our study is shorter than observed 
in randomized trials, yet it must be acknowledged that 
by eligibility criteria we included only patients with 
high-grade STS, in order to keep the two cohorts of 
patients as homogenous as possible. Grade is indeed one 
of the strongest prognostic factors in STS. The EORTC 
62931 trial (Woll et al. 2012), in which median DFS was 
90.6 months and median OS was 148.8 months, included 
a not-negligible portion of patients with low or inter-
mediate grade sarcomas (7 and 49 % respectively) that 
are characterized by better outcomes. Moreover, in our 
cohort, only roughly one-fourth of patients had surgery 
performed in a referral center, factor that is known to be 
Table 3  Hematological toxicities (maximum grade)
NA not applicable
Toxicities Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 6 1 2 14
Febrile neutropenia NA NA NA 10
Anemia 12 10 6 1
Thrombocytopenia 4 3 5 1
Table 4  Non-hematological toxicities (maximum grade)
H&F hand and foot, GI gastrointestinal
Toxicities Grade 1 Grade 2 Grade 3 Grade 4
Nausea/vomiting 9 10 2 0
Mucositis 0 4 0 0
Fatigue 5 1 1 0
H&F syndrome 0 1 0 0
Other GI 4 0 0 1
Cardiotoxicity 1 0 0 0
Neuropathy c/p 1 2 1 0
Other toxicities 16 8 3 1
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crucial for survival (ESMO guidelines 2012; Rossi et al. 
2013; Ray-Coquard et al. 2004; Clasby et al. 1997). Also, 
only a half of the patients in our study had STS located in 
the limbs or girdles, sites where adjuvant chemotherapy 
has shown a better activity (SMAC 1997). Indeed, when 
we consider only the patients with neoplasm of extremi-
ties, the median DFS is 82.4 months, thus comparable to 
literature data.
Among the factors that may influence the impact of 
chemotherapy on survival is dose intensity. In the update 
of the Italian Sarcoma Group trial (Frustaci et al. 2003), the 
benefit in OS was lost at a longer follow-up of 89.6 months 
(p = 0.07), but when considering only patients receiving 
DI ≥ 85 % the trend in favor of chemotherapy is main-
tained (p = 0.034). In our study 72 % of the patients in the 
ACT group received a DI ≥ 85 %, and this must be taken 
into account for the advantage we found from adjuvant 
chemotherapy.
Also, more than 80 % of our patients received more 
than three cycles of adjuvant chemotherapy, and we did not 
find any difference in outcomes compared to those patients 
receiving three cycles or less. This is likely due to the small 
number of subjects who received less than three cycles; 
nonetheless, such results are consistent with those reported 
by Gronchi and colleagues (Gronchi et al. 2012) showing 
non-inferiority of three cycles of chemotherapy compared 
to five cycles.
As for the tolerability and treatment-related toxicity, 
55 % of the patients in the chemotherapy group expe-
rienced grade 3–4 toxicities. In five cases, toxicity led to 
early interruption of therapy. Anemia was the most frequent 
hematological toxicity, with neutropenia being the second 
most frequent hematological toxicity, present in about a 
half of the patients and with cases of febrile neutropenia 
successfully managed with no major complications. These 
results are consistent with the study of Frustaci and col-
leagues, where 58 % of patients developed severe neutro-
penia, whereas in the study by Gronchi et al. severe neutro-
penia was observed in 77 % of patients who received three 
cycles of chemotherapy and in 83 % of those who received 
five cycles.
As for non-hematological toxicities, the most frequently 
reported were nausea/vomiting, which were mainly low 
grade, present in two-thirds of patients. There was only a 
slight and asymptomatic reduction in left ventricular ejec-
tion fraction in one patient, without other cardiac toxicities. 
It must be observed that patients were selected for suit-
ability to anthracyclines and pegylated liposomal doxoru-
bicin was used instead of conventional anthracycline in two 
cases.
Globally, in our experience, treatment with anthracy-
cline and ifosfamide despite its toxicity was feasible with 
no major side effects and no serious cardiac events.
Conclusion
Even with the limits given by the retrospective nature of 
the study, our results confirm that adjuvant chemotherapy 
with anthracycline and ifosfamide after definitive surgery 
confers benefits in terms of DFS and OS in patients with 
high-risk sarcoma, namely deep-seated sarcomas which 
are larger than 5 cm and high grade. The greatest benefit is 
seen for patients with sarcomas of the extremities.
Given the high rate of hematological toxicity, and con-
sidering our results that are consistent with published data 
(Gronchi et al. 2012), three cycles of adjuvant chemo-
therapy with anthracycline and ifosfamide in full doses, 
with adequate support, may be recommended in selected 
patients with high risk radically resected STS.
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